Fund is pleased to announce that Open Philanthropy, a grantmaking organization based in San Francisco, California, has awarded funding for efforts to cultivate new partnerships and secure resources ...
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities ...
Fintel on MSN6h
HSBC Upgrades Moderna (MRNA)Fintel reports that on November 18, 2024, HSBC upgraded their outlook for Moderna (NasdaqGS:MRNA) from Hold to Buy. Analyst ...
The funding for the gene editing program is in addition to a separate $15 million investment in ReCode that the Foundation ...
The COVID-19 pandemic has dramatically transformed our understanding of public health, particularly when it comes to ...
The BiaB advantages over traditional methods of RNA manufacturing, include high throughput of high-quality pharmaceutical ...
Advanced genetic testing helped clinicians identify novel SMN1 mutations in two children in China, and correctly diagnose ...
Quotient Sciences, a leading global drug development and manufacturing accelerator, today announced the installation of Centillion’s™ proprietary Biofoundry-in-a-Box (BiaB™), the first multi-product ...
Trace Neuroscience has launched in the U.S. with over $100 million in financing and a goal to develop its UNC13A-targeted ...
A new technology that delivers two halves of a gene separately could enable gene therapy treatments of muscular dystrophies.
Most people don’t enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such as those made from messenger RNA (mRNA), that can be sprayed and inha ...
StitchR makes it possible to deliver larger payloads with current vectors, expanding the list of diseases targetable by gene therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback